Table 1.
Baseline characteristics of the RA patients who received tocilizumab and were enrolled in this retrospective study
| All cases (n = 229) | Concomitant methotrexate | Prior use of anti-TNF | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| With MTX (n = 127) | Without MTX (n = 102) | With anti-TNF (n = 144) | Without anti-TNF (n = 85) | ||||||||||||
| Mean | SD | Median | 25 percentile | 75 percentile | Minimum | Maximum | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Female (%) | 84.0 | 82.0 | 87.0 | 81.0 | 89.0 | ||||||||||
| Age (years old) | 58.7 | 13.6 | 61.0 | 52.0 | 68.0 | 15.0 | 88.0 | 55.5 | 14.0 | 62.8 | 11.9 | 56.5 | 14.3 | 62.4 | 11.4 |
| RA duration (years) | 12.4 | 11.1 | 10.0 | 4.0 | 18.0 | 0.1 | 72.0 | 10.3 | 8.5 | 15.0 | 13.2 | 12.1 | 10.4 | 12.9 | 12.2 |
| Biologics—history (%) | 63.0 | 72.0 | 51.0 | 100.0 | 0.0 | ||||||||||
| Prior use of infliximab (%) | 37.0 | ||||||||||||||
| Prior use of etanercept (%) | 41.0 | ||||||||||||||
| Prior use of adalimumab (%) | 2.0 | ||||||||||||||
| MTX use (%) | 55.0 | 100.0 | 0.0 | 64.0 | 41.0 | ||||||||||
| MTX dose (mg/week) | 8.7 | 3.1 | 8.0 | 6.0 | 10.0 | 3.0 | 15.0 | 8.7 | 3.1 | 8.7 | 3.1 | 8.8 | 2.9 | ||
| Other DMARD use (%) | 34.0 | ||||||||||||||
| Corticosteroid use (%) | 76.0 | 75.0 | 76.0 | 72.0 | |||||||||||
| Prednisolone dose (mg/day) | 5.3 | 3.2 | 5.0 | 3.0 | 6.0 | 0.5 | 20.0 | 5.3 | 2.6 | 5.4 | 3.8 | 78.0 | 2.9 | 5.1 | 3.7 |
| Swollen Joint Count (/28) | 7.7 | 5.7 | 7.0 | 3.0 | 11.0 | 0.0 | 28.0 | 7.1 | 5.1 | 8.6 | 6.3 | 8.0 | 5.9 | 7.4 | 5.5 |
| Tender Joint Count (/28) | 7.9 | 6.5 | 6.0 | 3.0 | 12.0 | 0.0 | 28.0 | 6.7 | 5.4 | 9.3 | 7.3 | 8.0 | 6.7 | 7.6 | 6.1 |
| CRP (mg/dl) | 3.2 | 3.0 | 2.4 | 0.9 | 4.5 | 0.0 | 18.0 | 3.2 | 2.8 | 3.1 | 3.3 | 3.2 | 3.0 | 3.1 | 3.1 |
| ESR (mm/1 h) | 62.6 | 29.8 | 63.0 | 41.5 | 83.5 | 3.0 | 149.0 | 61.4 | 28.5 | 64.1 | 31.4 | 62.1 | 28.5 | 63.5 | 32.1 |
| General Health (mm) | 56.5 | 23.5 | 54.0 | 41.5 | 75.3 | 0.0 | 100.0 | 53.2 | 23.8 | 60.5 | 22.6 | 56.6 | 22.8 | 56.1 | 24.8 |
| DAS28-ESR | 5.7 | 1.2 | 5.6 | 4.9 | 6.6 | 1.6 | 9.0 | 5.5 | 1.2 | 5.9 | 1.3 | 5.7 | 1.3 | 5.7 | 1.2 |
| DAS28-CRP | 5.0 | 1.2 | 4.8 | 4.1 | 5.8 | 1.7 | 8.3 | 4.8 | 1.1 | 5.2 | 1.3 | 5.0 | 1.2 | 4.9 | 1.2 |
| DAS28 remission (%) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | ||||||||||
| DAS28 low (%) | 1.0 | 2.0 | 0.0 | 1.0 | 1.0 | ||||||||||
| DAS28 moderate (%) | 30.0 | 35.0 | 24.0 | 31.0 | 29.0 | ||||||||||
| DAS28 high (%) | 68.0 | 62.0 | 75.0 | 68.0 | 68.0 | ||||||||||
| HAQ-DI | 1.6 | 0.8 | 1.5 | 1.0 | 2.2 | 0.0 | 3.0 | 1.4 | 0.7 | 1.7 | 0.8 | 1.5 | 0.7 | 1.6 | 0.8 |
RA Rheumatoid arthritis, SD standard deviation, MTX methotrexate, TNF tumor necrosis factor, DMARD disease-modifying antirheumatic drug, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 Daily Activity Score based on 28 joints, HAQ-DI Health Assessment Questionnaire Disability Index